Stockscreener 앱 받기
4.08
4.88%
0.19
전일 마감가:
$3.89
열려 있는:
$3.93
하루 거래량:
999.10K
Relative Volume:
2.58
시가총액:
$250.58M
수익:
$45.15M
순이익/손실:
$-39.23M
주가수익비율:
-2.2307
EPS:
-1.829
순현금흐름:
$-18.93M
1주 성능:
+12.09%
1개월 성능:
+34.65%
6개월 성능:
-43.96%
1년 성능:
-24.16%
1일 변동 폭
$3.84
$4.285
1주일 범위
$3.56
$4.455
52주 변동 폭
$2.20
$7.95
Trisalus Life Sciences Inc Stock (TLSI) Company Profile
명칭
Trisalus Life Sciences Inc
전화
415 336 8917
주소
6272 WEST 91ST AVENUE, WESTMINSTER
Compare TLSI vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TLSI
Trisalus Life Sciences Inc
|
4.08 | 250.58M | 45.15M | -39.23M | -18.93M | -1.829 |
ABT
Abbott Laboratories
|
88.41 | 153.99B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
307.80 | 118.00B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
79.34 | 101.86B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
45.29 | 67.32B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
87.36 | 50.30B | 6.30B | 1.07B | 1.09B | 1.8406 |
Trisalus Life Sciences Inc Stock (TLSI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-13 | 개시 | Lake Street | Buy |
| 2024-12-17 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-11-11 | 개시 | ROTH MKM | Buy |
| 2024-10-25 | 개시 | Northland Capital | Outperform |
| 2024-09-16 | 개시 | Oppenheimer | Outperform |
| 2024-05-30 | 개시 | Canaccord Genuity | Buy |
모두보기
Trisalus Life Sciences Inc 주식(TLSI)의 최신 뉴스
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TriSalus Life Sciences Inc.TLSI - PR Newswire
TriSalus Life Sciences Inc (TLSIW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
TriSalus Life Sciences Inc (TLSIW) Institutional Confidence - TradingKey
TriSalus Life Sciences Inc (TLSIW) Valuation: PE, PB & Fair Value Analysis - TradingKey
TriSalus Life Sciences Inc (TLSIW) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
TriSalus Life Sciences Inc (TLSIW) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
TriSalus Life Sciences Inc (TLSI) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
TriSalus Life Sciences Inc (TLSI) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
TriSalus Life Sciences Inc (TLSI) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
TriSalus Life Sciences Inc (TLSI) Institutional Confidence - TradingKey
TriSalus Life Sciences Inc (TLSI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
TriSalus Life Sciences Inc (TLSI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
TriSalus Life Sciences Inc (TLSI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TriSalus Life Sciences Inc (TLSI) Valuation: PE, PB & Fair Value Analysis - TradingKey
TriSalus Life Sciences Inc (TLSIW) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
TriSalus Life Sciences Inc (TLSIW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TriSalus Life Sciences Inc (TLSIW) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
TLSI Investors Have Opportunity to Join TriSalus Life Sciences, Inc. Fraud Investigation with the Schall Law Firm - GlobeNewswire
Richard Marshall Accepts New Role at TriSalus Life Sciences - Medical Product Outsourcing
TriSalus Life Sciences Warrants (TLSIW) Hold Steady Near Support in Quiet TradingAndrews Pitchfork - newsline.com
TLSI Q1 2026 Earnings: EPS Surprise of 118.86% Drives Stock HigherAnalyst Drop Coverage - newsline.com
TriSalus Life Sciences (TLSI) Q1 2026 Earnings: Surprise Profitability as EPS Beats Estimates by 118.86% - newsline.com
TLSI News | TRISALUS LIFE SCIENCES INC (NASDAQ:TLSI) - ChartMill
TriSalus Life Sciences (TLSI) Gains 2.88% as Stock Approaches Key Resistance LevelWave Extension - newsline.com
TriSalus Life Sciences to Host Virtual KOL Event on June 24 Featuring New Real-World Evidence for Pressure-Enabled Drug Delivery™ in Liver Cancer - Stock Titan
TriSalus Life Sciences Inc. (TLSI) Q1 2026 Earnings: Strong EPS Surprise Driven by Operational ProgressFree Cash Flow Trends - newsline.com
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against TriSalus Life Sciences, Inc. (TLSI) And Encourages Shareholders to Reach Out - ACCESS Newswire
TLSI INVESTOR ALERT: Holzer & Holzer, LLC Investigation of TriSalus Life Sciences, Inc. - GlobeNewswire
TriSalus Life Sciences, Inc. (TLSI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages TriSalus Life Sciences, Inc. (TLSI) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
2026-06-03 | Bronstein, Gewirtz & Grossman, LLC Encourages TriSalus Life Sciences, Inc. (TLSI) Shareholders to Inquire about Securities Investigation | NDAQ:TLSI | Press Release - Stockhouse
TSLI Investors Have Opportunity to Join TriSalus Life Sciences, Inc. Fraud Investigation with the Schall Law Firm - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Is Investigating TriSalus Life Sciences, Inc. (TLSI) And Encourages Investors to Connect - ACCESS Newswire
TLSI Q1 2026 Earnings: Surprise EPS Beat Despite No Revenue, Stock DeclinesMargin Guidance - newsline.com
Bronstein, Gewirtz & Grossman, LLC Encourages TriSalus Life Sciences, Inc. (TLSI) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
2026-06-01 | Bronstein, Gewirtz & Grossman, LLC Encourages TriSalus Life Sciences, Inc. (TLSI) Stockholders to Inquire about Securities Investigation | NDAQ:TLSI | Press Release - Stockhouse
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against TriSalus Life Sciences, Inc. (TLSI) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
TLSI Q1 2026 Earnings: Surprise Profit Beats Analyst Estimates, Shares RallySurprise Factor Analysis - newsline.com
Number of shareholders of TriSalus Life Sciences, Inc. – NASDAQ:TLSI - TradingView
TriSalus Life Sciences, Inc. (TLSI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
TriSalus Life Sciences Q1 2026 Earnings: Surprise EPS Profit of $0.03 Beats Estimates by 118.9%Forward Guidance Trends - newsline.com
Bronstein, Gewirtz & Grossman, LLC Is Investigating TriSalus Life Sciences, Inc. (TLSI) And Encourages Stockholders to Connect - ACCESS Newswire
TriSalus Life Sciences, Inc. (TLSI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
TriSalus Life Sciences, Inc. (TLSI) Investigation: Bronstein, Gew - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against TriSalus Life Sciences, Inc. (TLSI) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
TriSalus Life Sciences (TLSI) Falls Over 5% as Stock Tests Key Support Near $3.10Stop Hunt - The Legal Advocate
Bronstein, Gewirtz & Grossman, LLC Encourages TriSalus Life Sciences, Inc. (TLSI) Investors to Inquire about Securities Investigation - ACCESS Newswire
Investigation launched into TriSalus Life Sciences after Q1 revenue misses estimates and cuts full-year guidance - Pluang
TLSI Q1 2026 Earnings: EPS Surprises Positively Despite No Revenue, Stock DeclinesProfit Warning Alert - Newser
Bronstein, Gewirtz & Grossman, LLC Is Investigating TriSalus Life Sciences, Inc. (RLSI) And Encourages Stockholders to Connect - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating TriSalus Life - The National Law Review
Trisalus Life Sciences Inc (TLSI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Trisalus Life Sciences Inc 주식 (TLSI) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Wahlstrom Mats | Director |
May 15 '26 |
Buy |
2.53 |
60,000 |
151,800 |
147,555 |
| Stansky Michael P | Director |
May 15 '26 |
Buy |
2.50 |
410,000 |
1,025,000 |
1,240,722 |
| Stansky Michael P | Director |
May 15 '26 |
Buy |
2.50 |
200,000 |
500,000 |
399,698 |
| Szela Mary T | CEO and President |
May 15 '26 |
Buy |
2.59 |
39,682 |
102,776 |
1,065,215 |
| Patience David | Chief Financial Officer |
May 15 '26 |
Buy |
2.43 |
7,100 |
17,253 |
275,757 |
| Gordon Gary B. | Director |
May 15 '26 |
Buy |
2.46 |
10,000 |
24,600 |
72,510 |
| Devlin Jodi | Chief of Clinical Operations |
Mar 12 '26 |
Sale |
4.09 |
1,772 |
7,247 |
97,637 |
| Devlin Jodi | Chief of Clinical Operations |
Mar 11 '26 |
Sale |
4.13 |
1,162 |
4,799 |
99,409 |
| Devlin Jodi | Chief of Clinical Operations |
Mar 16 '26 |
Sale |
4.12 |
273 |
1,125 |
97,364 |
| Cox Bryan F. | Chief of Research |
Mar 12 '26 |
Sale |
4.09 |
1,467 |
6,000 |
163,994 |
0.93%
자본화:
|
볼륨(24시간):